IAVI B001

Status:Completed
Phase:I
Principal Investigator(s):Michael Keefer
Objective:The purpose of this study is to evaluate the safety and immunogenicity of Ad35-GRIN/ENV HIV vaccine and Ad35-GRIN HIV vaccine   Last updated March 31, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionAd35-GRIN/ENV: 2x10^9 vp
Mode of Delivery
ARMsExperimental
DescriptionAd35-GRIN/ENV: 2x10^10 vp
Mode of Delivery
ARMsExperimental
DescriptionAd35-GRIN/ENV: 2x10^11 vp
Mode of Delivery
ARMsExperimental
DescriptionAd35-GRIN at 1x10^10 vp
Mode of Delivery
ARMsExperimental
Results: A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults
Official Code: NCT00851383
Trial Sponsors: IAVI, University of Rochester
Start Date
End Date
March 31, 2009
August 31, 2011
Enrollment:56
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women